Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Brii Biosciences Limited ( (HK:2137) ) just unveiled an update.
Brii Biosciences Limited has entered into a licensing agreement with Joincare Pharmaceutical Group to develop and commercialize BRII-693, a novel antibiotic for multidrug-resistant infections, in Greater China. This partnership leverages Joincare’s expertise in manufacturing and commercialization, aiming to address the critical unmet clinical needs for hospital antibiotics in the region, thereby enhancing Brii Biosciences’ strategic positioning in the anti-infection market.
The most recent analyst rating on (HK:2137) stock is a Hold with a HK$1.00 price target. To see the full list of analyst forecasts on Brii Biosciences Limited stock, see the HK:2137 Stock Forecast page.
More about Brii Biosciences Limited
Brii Biosciences Limited is a biopharmaceutical company focused on developing innovative therapies for infectious diseases. Their primary products include novel antibiotics targeting multidrug-resistant bacterial infections, with a market focus on Greater China.
Average Trading Volume: 3,933,697
Technical Sentiment Signal: Hold
Current Market Cap: HK$1.24B
See more insights into 2137 stock on TipRanks’ Stock Analysis page.